Sep 05, 2024
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
Sep 05, 2024
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
Jul 16, 2024
Hoth Therapeutics Expands Clinical Trial for Cancer Patients
May 01, 2024
Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024
Mar 19, 2024
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
Feb 29, 2024
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
Feb 13, 2024
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
Jan 18, 2024
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
Feb 25, 2021
Hoth Therapeutics Retains RedChip to Increase Investor Awareness
Feb 24, 2021
Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment
Feb 18, 2021
Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)
Feb 10, 2021
Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv
Feb 08, 2021
Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients
Jan 20, 2021
Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication
Jan 05, 2021
Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules
Dec 23, 2020
Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients
Dec 21, 2020
Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model
Nov 03, 2020
Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
Nov 02, 2020
Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine
Sep 01, 2020
Hoth Therapeutics' Chief Scientific Officer, Dr. Stefanie Johns, to Appear on One America News Network on Tuesday, September 1, 2020